Abstract
Human lactoferrin is a component of the non-specific immune system with distinct antiviral properties. Here, we used HS-adapted alphaviruses as a tool to investigate the mechanism of lactoferrin's antiviral activity. Lactoferrin inhibited infection of BHK-21 cells by HS-adapted Sindbis virus (SIN) or Semliki Forest virus (SFV). In a model system consisting of liposomes containing lipid-conjugated heparin as a receptor analog, lactoferrin interfered with receptor interaction of HS-adapted SIN or SFV. On the other hand, low-pH-induced fusion of the virus with the liposomes, which occurs independently of virus-receptor interaction, was unaffected. Chargemodified human serum albumin, with a net positive charge, had a similar antiviral effect against HS-adapted SIN and SFV, suggesting that the antiviral activity of lactoferrin is related to its positive charge. It is concluded that human lactoferrin inhibits viral infection by interfering with virus-receptor interaction rather than by affecting subsequent steps in the viral cell entry or replication processes.
Introduction
Human lactoferrin (hLF) is an 80-kD cationic glycoprotein belonging to the transferrin family of Fe 3+ -transporting proteins (see Kanyshkova et al., 2001 for review) . hLF is produced by epithelial cells and, as a result, is present in mucosal secretions such as tears, saliva, nasal exudate, gastrointestinal fluids, and seminal and vaginal fluids. Furthermore, hLF is present in high concentrations in human breast milk. Breast feeding is known to protect newborns against a variety of infections including viral infections (Hanson and Korotkova, 2002) . Viruses against which lactoferrin possesses antiviral activity include human herpes simplex virus types 1 and 2 (Hasegawa et al., 1994) , adenovirus (Arnold et al., 2002) , human immunodeficiency virus (Harmsen et al., 1995 , Puddu et al., 1998 , Swart et al., 1999 , hepatitis C virus (Ikeda et al., 2000) , human cytomegalovirus (Hasegawa et al., 1994 , Harmsen et al., 1995 , Swart et al., 1999 , poliovirus (Marchetti et al., 1999) hantavirus (Murphy et al., 2000) , and enterovirus 71 (Lin et al., 2002) (for a review, see van der Strate et al., 2001) .
Most of the above studies on the antiviral activity of hLF suggest that the protein inhibits virus entry into cells rather than later phases of viral replication. Lactoferrin, in principle, can prevent virus cell entry by binding to the virus particle or by binding to cell-surface molecules that viruses use either as receptors or co-receptors. In either case, lactoferrin would prevent viral attachment to the cell surface van der Strate et al., 2001) . It has been suggested that binding of hLF to cell-surface heparan sulfate glycosaminoglycans (HSPGs) is involved in inhibition of viral infection . Numerous studies have shown that viruses from different families interact with HSPGs. Examples include Sindbis virus (Klimstra et al., 1998; Byrnes and Griffin, 1998) , Venezuelan equine encephalitis virus (Bernard et al., 2000) , Ross River virus (Heil et al., 2001) , adeno-associated virus type 2 (Summerford and Samulski, 1998) , foot-and-mouth disease virus (Jackson et al., 1996; Sa-Carvalho et al., 1997) , herpesviruses (Compton et al., 1993; Shukla and Spear, 2001; Birkmann et al., 2001; Trybala et al., 2002) , human immunodeficiency virus (Patel et al., 1993) , echovirus (Goodfellow et al., 2001) , dengue virus (Chen et al., 1997; Hilgard and Stockert, 2000; Germi et al., 2002) , and yellow fever virus (Germi et al., 2002) . It is important to note that the ability of viruses to interact with HSPGs is often acquired by cell culture adaptation. However, affinity for HSPGs has also been demonstrated in clinical isolates, e.g. for Herpes Simplex virus type 1 (Trybala et al., 2002) and echovirus (Goodfellow et al., 2001) .
In order to determine whether hLF indeed exerts antiviral activity through interference with virus binding to HSPG receptors, we studied the effects of hLF on the cell entry and receptor binding of alphaviruses, which are adapted to interaction with HSPGs. Alphaviruses are enveloped positive-strand RNA viruses belonging to the family Togaviridae (reviewed by Straus and Straus, 1994) . Cell entry of alphaviruses is mediated by the heterodimeric E1/E2 envelope glycoprotein. Infection of a host cell is initiated by the interaction of the E2 glycoprotein with an attachment receptor on the cell surface (Davis et al., 1986; Russell et al., 1989; McKnight et al., 1996; Tucker et al., 1997) , after which the receptor-bound virion is internalized through endocytosis. This is followed by E1-mediated fusion of the viral envelope with the endosomal membrane, which delivers the viral RNA to the cytosol (Helenius et al., 1980; Marsh et al., 1982; Marsh et al., 1983) . For Sindbis virus (SIN), Klimstra et al. (1998) identified positively charged amino acid substitutions in the viral spike protein E2 which arise when the virus is passaged over BHK-21 cells and are responsible for interaction of the virion with HS.
In the present study, the antiviral activity of hLF on a HS-adapted SIN mutant (TRSB), a non-adapted SIN strain (TR339), and two laboratory strains of Semliki Forest virus (SFV) was determined. Using a model system involving liposomes containing lipid-conjugated heparin (HepPE) as an attachment receptor analog for the virus (Smit et al., 2002) , we demonstrate that hLF prevents infection of a host cell by alphaviruses through blocking of the viral attachment receptors on the cell surface.
Experimental Procedures
Viruses -Viruses were generated from cDNA clones. Construction of the consensus SIN AR339 clone pTR339 and the HS-adapted SIN clone pTRSB has been described previously (Klimstra et al., 1998; Klimstra et al., 1999; McKnight et al., 1996) . Construction of the SFV clone pSFV4 (pSP6-SFV4) has been described previously . This clone was generated from a laboratory strain of SFV, adapted to growth on BHK-21 cells. Construction of pSFV3-LacZ, a recombinant construct based on clone pSFV4, has been described previously . A plaque-purified laboratory strain of SFV, also highly adapted to growth on BHK-21 cells, was a generous gift of Dr. Margaret Kielian (Albert Einstein College of Medicine, Bronx, N.Y.). SIN TR339, SIN TRSB, and SFV-LacZ were produced by high-efficiency electroporation of BHK-21 cells with in vitro RNA transcripts of linearized cDNA as described previously . pSFV3-LacZ RNA was coelectroporated with pSFV-Helper1 RNA. Plaque-purified SFV was propagated on BHK-21 cells. The cells were cultured in Glasgow's modification of Eagle's minimal essential medium (Invitrogen, Breda, The Netherlands), supplemented with 5% fetal calf serum, 10% tryptose phosphate broth, 200 mM glutamine, 25 mM HEPES, and 7.5% sodium bicarbonate (BHK-medium) at 37°C and 5% CO 2 . Viruses released from the cells at 20-hr post-transfection or -infection were harvested, and these stocks were subsequently used for production of pyrene-or [
35 S]methionine-labeled SIN or SFV particles, as previously described (Bron et al., 1993; Smit et al., 1999) . The viruses were characterized by plaque assay on BHK-21 cells (Klimstra et al., 1998) , phospholipid analysis (Böttcher et al., 1961) , and protein determination (Peterson, 1977) . The purity of the viruses was confirmed by SDS-PAGE.
Proteins -hLF was obtained from Numico Research BV (Wageningen, The Netherlands), HSA was purchased from the Central Laboratory of the Blood Transfusion Services (Amsterdam, The Netherlands). Cat-HSA was prepared as described previously (Swart et al., 1999) .
Liposomes -Liposomes (large unilamellar vesicles) consisted of phosphatidylcholine (PC), phosphatidylethanolamine (PE), sphingomyelin (SPM), and cholesterol (Chol) in a molar ratio of 0.83; 0.83; 0.83; 1.25, supplemented with 0.02 mol% HepPE (binding experiments) or 0.01 mol% HepPE (fusion experiments) based on total phospholipid. The phospholipids and cholesterol were obtained from Avanti Polar Lipids (Alabaster, AL). The HepPE conjugate, consisting of heparin (from porcine intestinal mucosa; average molecular weight, 10,000; Scientific Protein Laboratories, Wannakee, WI) coupled to dipalmitoyl-PE, was synthesized and purified as described previously (Sugiura et al., 1993) . The liposomes were prepared by dialysis in the presence of n-octyl-β-D-glucopyranoside (OGP; Calbiochem, Darmstadt, Germany), followed by freeze-thaw-extrusion as described previously (Smit et al., 2002) .
Infectivity assays -Virus entry was determined by plaque formation or LacZ gene expression. For the plaque assay, monolayers of CHO-K1 cells were grown in 12-well plates in HAM's F12 medium with L-glutamine (Invitrogen, Breda, The Netherlands) supplemented with 10% fetal calf serum at 37°C at 5% CO 2 . The monolayers were preincubated for 1-1.5 hr with 200 µg/ml hLF in medium or with medium alone. Serial dilutions of virus in 0.6 ml of medium containing 200 µg/ml hLF or medium alone were added to the cell monolayers. After 1 h at 37°C, the virus-containing medium was removed from the monolayers and the cells were washed 3 times with PBS. The washed monolayers were overlaid with a 1:1 dilution of medium with or without 400 µg/ml hLF and a 2% aqueous solution of methylcellulose (Sigma). After 2-3 days of incubation at 37°C, the plaques were counted.
For the transfection assay, monolayers of BHK-21 cells were grown in 24-well plates in BHK-medium (see above). The monolayers were pre-incubated for 1-1.5 h with 200 µg/ml hLF in medium or with medium alone at 37°C. After removal of the medium, 0.3 ml per well of a dilution of recombinant SFV-LacZ virus was added. The virus was diluted in medium with or without 200 µg/ml hLF. After 1-h incubation at 37°C, 5% CO 2 the virus solution was removed and the monolayers were washed 2-3 times with PBS and 1 ml of medium with or without 200 µg/ml hLF was added and incubated overnight at 37°C, 5% CO 2 . Subsequently, the cells were washed once with PBS and fixed for 5 min at room temperature with a fresh mixture of 2% paraformaldehyde, 0.2% glutaraldehyde in PBS with Ca 2+ and Mg
2+
. Following this, the cells were washed once with PBS and incubated for 2 h at 37°C with 0.1% 5'-bromo-4-chloro-3-indolyl-β-D-galactopyranoside (X-Gal) (Roche Diagnostics, Almere, The Netherlands), 5 mM K 4 [Fe(CN) 6 , 5 mM K 3 [Fe(CN) 6 ], 2 mM MgCl 2 , 0.15 mM NaCl, and 25 mM HEPES (Sigma). Transfected cells appeared as blue cells.
Binding assays -Virus binding to BHK-21 cells was performed essentially as described previously (Klimstra et al., 1998; Byrnes et al.,1998; Smit et al., 2001) . Cells were grown in 12-well plates in BHK-medium at 37°C, 5% CO 2 . At 4°C, the medium was removed from the cells, which were then washed twice with ice-cold HNE supplemented with 0.5 mM CaCl 2 -0.5 mM MgCl 2 -1% FCS (HNE*). Approximately 10 4 cpm of [ 35 S]methionine-labeled virus was added to each well in 150 µl of HNE* containing various concentrations of hLF. Subsequently, the plates were rocked for a period of 1.5-2 hr at 4°C. The virus suspension was removed and the cells were washed twice with ice-cold HNE*. Cells were trypsinized and collected after which virus binding was quantified by liquid-scintillation counting.
Virus binding to liposomes was assessed by a coflotation assay, as described previously (Smit et al., 2002 (Smit et al., , 2003 . Briefly, liposomes (200 µM) were incubated in 5 mM HEPES, 150 mM NaCl, and 0.1 mM EDTA (pH7.4) (HNE) containing various concentrations of hLF, HSA, or cat-HSA for 10 min at 37°C, after which [
35 S]methionine-labeled virus (ranging from 10 5 to 10 6 cpm) was added to the mixture and allowed to incubate for another 10 min at 37°C. Then, 0.1 ml of the mixture was added to 1.4 ml of 50% (w/v) sucrose in HNE, and this was layered on a cushion of 0.5 ml of 60% (w/v) sucrose in HNE. On top of this, 1.0-ml volumes of 35, 20, and 5% (w/v) sucrose in HNE were layered. After centrifugation at 4°C for 2 hr at 150,000 × g in a Beckman SW50 rotor, the gradient was fractionated into 10 samples, starting from the top. The radioactivity found in the top four fractions, relative to the total amount of radioactivity, was taken as a measure of virus-liposome binding.
Fusion assay -Fusion of pyrene-labeled SIN-TRSB with HepPE liposomes was performed as described elsewhere (Smit et al., 2002 (Smit et al., , 2003 . Virus and liposomes were mixed in HNE containing different concentrations of hLF in a magnetically stirred and thermostatted (37°C) quartz cuvette in an AB2 fluorometer (SLM/Aminco, Urbana, IL). Fusion was triggered by injecting a small volume of 0.1 M MES (Sigma), 0.2 M acetic acid, pretitrated with NaOH to achieve pH 5.0. Fusion was monitored continuously as a decrease in pyrene excimer fluorescence (excitation at 345 nm and emission at 480 nm) by dilution of the lipid probe from the viral membrane into the target membrane. The fusion scale was calibrated such that 0% fusion corresponded to the initial excimer fluorescence intensity and 100% fusion to complete dilution of the probe.
Toxicity assay -The cytotoxicity of human lactoferrin on BHK-21 cells was tested according to standard methods using the cell proliferation reagent 2-(4-iodophenyl)-3-(4-nitrophenyl)-5-(2,4-disulfophenyl)-2 H-tetrazolium, monosodium salt (WST-1) (Roche Diagnostics, Almere, The Netherlands). On day 1, cells were plated at 10 4 per well in 96-wells plates in BHK-21 medium containing various concentrations of human lactoferrin. On day 3, the medium was removed from the cells, after which 10 µl of WST-1 reagent was added to each well. After 1, 2, 3, and 4 hr the optical density (OD) was measured at 450 nm.
Results

Inhibition of HS-Adapted SIN and SFV Infection by hLF
To determine if hLF has antiviral activity against HS-adapted alphaviruses we performed a plaque titration in the presence of hLF and quantified the formation of viral plaques. CHO cells were pre-incubated with 200 µg/ml hLF. The same concentration of hLF was maintained throughout the infection and in the overlay. The cells were infected with SIN strains TR339 and TRSB and a laboratory strain of SFV. TR339 is a non-HS-adapted SIN strain, whereas TRSB and the laboratory strain of SFV are known to use HS as a cell-attachment receptor (Klimstra et al., 1998; Smit et al., 2002) . Infection of CHO cells by the SIN strain TR339 was not inhibited by hLF (Fig. 1) . In contrast, the plaque titer was strongly reduced for the HS-adapted SIN strain TRSB in the presence of hLF (Fig. 1) . The laboratory strain of SFV was also strongly inhibited by hLF. No cytotoxic effect of hLF on the cells was observed during the experiments.
The above results were confirmed by the use of recombinant SFV carrying the lacZ gene. The recombinant virus was derived from a SFV clone (here denoted pSFV4) generated from a laboratory strain passaged over BHK cells . In the presence of 200 µg/ml hLF, transfection of BHK cells was completely abolished (Fig. 2) . A standard cytotoxicity assay excluded the possibility that hLF was cytotoxic to these cells. In addition, hLF did not change the pH of the medium significantly up to a concentration of 2.5 mg/ml (not shown). The results depicted in Fig. 1 and Fig. 2 show that hLF inhibits the infection of cells by HS-adapted SIN or SFV, whereas non-adapted SIN remains unaffected. 
Inhibition of Binding of SIN TRSB and SFV4 to BHK-21 Cells by hLF
To determine whether the inhibitory action of hLF shown in Fig. 1 and Fig. 2 is exerted by prevention of binding of the HS-adapted viruses to cells, cell-binding experiments were carried out with BHK-21 cells as described earlier (Byrnes and Griffin, 1998; Klimstra et al., 1998; Smit et al., 2001) . Radiolabeled virus was allowed to bind to cells at 4°C in the presence of various concentrations of hLF. Unbound virus was removed by washing, and bound virus was quantified by liquid-scintillation counting of trypsinized cells. Fig. 3 shows that binding of the HS-adapted SIN strain TRSB to BHK-21 cells was inhibited by hLF in a dose-dependent manner. Cell binding of SFV produced from the pSFV4 clone (see previous section; denoted as SFV4) was strongly inhibited by hLF. These results show that binding of both SFV4 and TRSB to BHK-21 cells is strongly inhibited by hLF. The binding of SFV4 was inhibited more efficiently than binding of TRSB.
Effect of hLF on TRSB Binding to HepPE-Containing Liposomes
To demonstrate that the inhibition of binding of HS-adapted alphaviruses to cells by hLF specifically involves the blocking of the HS moiety of the receptor, we employed target liposomes containing lipid-conjugated heparin as a model (Smit et al., 2002) . Liposomes were pre-incubated with various concentrations of hLF at 37°C and pH 7.4. Subsequently, radiolabeled virus was added and the extent of virus-liposome binding was determined in a sucrose-density gradient flotation assay. Fig. 4 shows that in the absence of hLF more than 60% of the TRSB particles was bound to the HepPE- containing liposomes (Fig. 4A, squares, and Fig. 4B ). In agreement with earlier results (Smit et al., 2002) , there was no binding of virus to liposomes lacking HepPE in the membrane (Fig. 4A, circles) . Binding of TRSB to HepPE-containing liposomes was inhibited by hLF in a dose-dependent manner ( Fig. 4B; IC 50 = 0.12 µM) . These results show that binding of TRSB to liposomes at neutral pH, which requires the presence of HepPE in the target membrane (Smit et al., 2002) , is inhibited by hLF.
Alphavirus Fusion with HepPE-Containing Liposomes is not Inhibited by hLF
Fusion of alphaviruses with liposomes has been studied extensively in a model system in which fusion is monitored on-line using virus that is labeled biosynthetically with a fluorescent pyrene lipid probe (reviewed in Smit et al., 2003) . To determine if hLF has an inhibitory effect on TRSB fusion, the virus was mixed with HepPEcontaining liposomes, and fusion was triggered in the presence of hLF. As shown in Fig. 5 , hLF did not inhibit, but even slightly stimulated (curves a-c), TRSB fusion at concentrations that are in excess to the concentrations that strongly inhibit TRSB binding (Fig. 4B) . The results indicate that TRSB fusion was not inhibited by hLF and that the antiviral action of hLF is only exerted at the first step of viral entry (cell attachment). 
Inhibitory Effect of Positively Charged Human Serum Albumin
The cationic character of hLF was recently shown to be of importance for its antiviral activity against CMV (Beljaars et al., 2004) . To determine whether the inhibition of receptor interaction of HS-adapted alphaviruses by hLF is likewise a result of the positive charge of hLF, the effect of positively charged HSA (cat-HSA) on TRSB binding to HepPE-containing liposomes was studied. Fig. 6 shows that native HSA had no significant effect on TRSB binding to HepPE-containing liposomes. Introduction of a net positive charge into HSA results in a potent inhibitory effect on TRSB binding to HepPE-containing liposomes (Fig. 6 ). These findings indicate that protein charge plays a role in the inhibitory effect on virus binding to HepPE which was observed for hLF. Liposomes were pre-incubated at 37°C with increasing concentrations of HSA (circles) or cat-HSA (squares) before being mixed with radiolabeled virus at 37°C. The extent of virus binding to HepPE-containing liposomes as a function of HSA or cat-HSA concentration is shown. Binding was determined by sucrose density-gradient analysis as described in Materials and Methods.
Discussion
In this paper we studied the antiviral action of hLF. To determine the mechanism of antiviral activity we used alphaviruses adapted to HSPG as the attachment receptor (Klimstra et al., 1998 , Smit et al., 2002 . hLF strongly inhibited infection of cells by HS-adapted alphaviruses but did not inhibit infection by the non-adapted SIN strain TR339 (Fig. 1) . Use of 200 µg/ml hLF caused a 70% reduction in viral plaques for TRSB, 90% reduction for SFV, and no reduction for SIN-TR339. The antiviral action of hLF appeared to be exerted at the level of cell attachment because the protein interfered with virus-cell binding; more specifically, it interfered with the binding of the virus to liposomes containing HepPE as an attachment receptor analog. TRSB showed residual binding to BHK cells in the presence of high concentrations hLF. No residual binding of TRSB to HepPE-liposomes, containing solely the HepPE receptor analog, was observed in the presence of hLF. This observation suggests that TRSB is able to bind to other receptors on BHK cells that are not blocked by hLF. hLF did not inhibit virus fusion with HepPE-containing liposomes indicating that the antiviral activity of hLF is only exerted at the first step of viral entry.
hLF has the capacity to bind to certain viruses and block viral entry (Marchetti et al., 1996; van der Strate et al., 2001) . The antiviral activity of hLF against HS-adapted alphaviruses probably does not involve binding to the virus particles as hLF did not inhibit fusion of TRSB. In the latter process, the viral spike protein inserts into the target membrane (Wahlberg et al., 1992; Bron et al., 1993; Kielian, 1995) ; the insertion of the spike protein would be hindered by opsonization of the virion with hLF. Moreover, the presence of hLF caused an increase in the extent of fusion. The most probable explanation is that HepPE, by virus binding, restrains interaction of some viruses with the target membrane and that hLF, by preventing virus binding, removes this restraint.
Our results are consistent with other studies that have shown that hLF is able to bind to heparin and HS and that binding is mediated through two clusters of basic residues located within the first 33 residues of hLF (Mann et al., 1994; Wu et al., 1995; van Berkel et al., 1997; Yazidi-Belkoura et al., 2001) . The cluster of Arg residues in the first six amino acids of hLF (GRRRRS) is found to be mainly responsible for the interaction with glycosaminoglycans and may act synergistically with the second cluster (RKVR) located at position 28-31 to form the predominant glycosaminoglycan binding site of the protein. HSPGs are present on the cell surface of most eukaryotic cells. The glycosaminoglycan moiety HS of HSPGs is a highly sulfated disaccharide polymer and therefore possesses a net negative charge. Proteoglycans have a large variety of biological functions that are mediated by their glycosaminoglycan moieties (for reviews see Tumova et al., 2000 and Bernfield et al., 1999) . Interaction of viruses with HS can be a result of cell-culture adaptation, as reported for some viruses (Bernard et al., 2000; Heil et al., 2001; Jackson et al., 1996; Klimstra et al., 1998; Sa-Carvalho et al., 1997) . However, for some viruses the ability to bind HS has also been shown to be a feature of clinical isolates (Goodfellow et al., 2001; Trybala et al., 2002) . It remains to be shown that clinical isolates of other viruses also have HS binding capacity.
Therefore, studying the hLF-mediated interference of HS binding by viruses contributes to the accumulating knowledge about the potentials of hLF as an antiviral agent. Marchetti et al. (1996) studied the antiviral activity of lactoferrins on HSV-1 and assumed that lactoferrins block cell receptors, like HSPGs, for HSV-1 (Marchetti et al., 1996) . Our results are in agreement with the recent findings by Di Biase et al. (2003) , who showed that mixtures of bovine lactoferrin and heparin abolished the antiadenovirus effect of each compound alone and concluded that the anti-adenovirus activity of bovine lactoferrin involves blocking cell-surface HSPGs.
Charge-modified HSA also inhibited TRSB binding to HepPE-containing liposomes. This suggests that the antiviral activity of hLF is related to its positive charge. As shown in Fig. 6 , the binding of TRSB was inhibited at concentrations of cat-HSA that are lower than the inhibitory concentrations of hLF; the IC 50 values of cat-HSA and hLF are 0.03 µM and 0.12 µM, respectively. Structural features of the proteins are most likely involved in this difference since the isoelectric points of cat-HSA and hLF are similar (pI ~8). Overall, our results are in agreement with the recent observations of Beljaars et al. (2004) , who demonstrated the importance of the cationic character of lactoferrin in inhibiting viral infection of host cells with CMV, another HSinteracting virus.
The results in this paper demonstrate that one way by which hLF can inhibit infection of cells by viruses is by blocking the exposure of HS present on cell surfaces, thus making adherence of HS-using viruses impossible. Using a model system for viral attachment to HS, we demonstrated the HS-blocking action of hLF. In an earlier report (Smit et al., 2002) , we evaluated this model system and suggested that it may serve as a novel tool for the study of receptor interactions and membrane fusion properties of HSinteracting enveloped viruses. As demonstrated here, this model system is a useful tool for the clarification of the mechanisms of antiviral substances acting on HS-interacting viruses.
Acknowledgements
